Navigation Links
Correction to Earlier Release From Jewish Hospital and University of Louisville
Date:7/24/2009

LOUISVILLE, Ky., July 24 /PRNewswire-USNewswire/ -- In today's announcement regarding the use of stem cells in the treatment of heart failure, we failed to make a critical distinction. Louisville researchers and physicians have performed the world's first phase-one FDA-approved clinical trial using "c-kit-positive" adult cardiac stem cells to treat heart disease. The clinical trial is being conducted by a team of University of Louisville physicians at Jewish Hospital, in collaboration with Dr. Piero Anversa and his team at the Brigham and Women's Hospital in Boston.

Following the press conference Roberto Bolli, Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and Director of UofL's Institute for Molecular Cardiology, stated, "Another clinical trial is being conducted at another facility. The difference between what we have done and what another institute nationally has done is that we have injected a pure population of stem cells, the c-kit-positive cells. The other institution injected cardiosphere-derived cells, which are a mixture of primitive and partially differentiated cells, complicating the recognition of the actual therapeutic cell. Our study involves a specific, well-characterized population of undifferentiated cells: the c-kit-positive cardiac stem cells are self-renewing, clonogenic and multipotent, which are the fundamental properties of stem cells."

This is a small, but distinct difference than the procedure performed last month in California.

We regret any misunderstanding or confusion.


'/>"/>
SOURCE Jewish Hospital
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Avon Protection Systems Issues Correction/Clarification on ST53 SCBA System
2. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
3. Discovery Leads to Earlier Diagnosis of Type 1 Diabetes
4. Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Population Finds
5. New Data Support Earlier Suggested Guidance for Levels of Cell-Mediated Immunity in Pediatric Liver Transplant Patients
6. Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
7. deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator
10. CEL-SCI Corporation Releases Letter to Shareholders
11. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Arvinas LLC, a private biotechnology company creating ... today announced the presentation of new preclinical data on ... session at the American Society of Clinical Oncology 2017 ... FL. "The new data ... potential of PROTACs to drive durable and robust responses ...
(Date:2/17/2017)... Research and Markets has announced the addition of ... their offering. ... separate comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. ... Also, a six-year historic analysis is provided for these markets. Market data ...
(Date:2/17/2017)... 17, 2017  Featuring new and ... the  2017 HIMSS Conference & Exhibition (HIMSS17 ),  Royal ... global leader in health technology,  will ... population health management, acute healthcare informatics ... a highly secure, cloud-based ecosystem. Visitors ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Wells Pharmacy Network offers ... of controlled and non-controlled substances plus the ability to manage orders on their ... States now accept electronic prescriptions, according to the Office of the National Coordinator ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Carol Francis' goals for each and every seminar, session and class she ... demonstrate five different brainwave tools which help energize creativity, focus mental functions, enhance ...
(Date:2/17/2017)... ... 17, 2017 , ... Access today announced that it will ... February 19-23. Visitors to the company’s booth (#1778) will be the first to ... solution in healthcare . , Since it first introduced Electronic Signature more ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended CHI's 8th ... of clinical trial planning and management. Pharmica discussed the importance of effective project ... attendees stopping by Pharmica’s booth were able to demo its cloud-based Resource ...
(Date:2/17/2017)... GA (PRWEB) , ... February 17, 2017 , ... Like ... to reduce readmissions. Driven in large part by the Hospital Readmission Reduction Program (HRRP), ... been a key focus area for hospitals across the nation. While many providers are ...
Breaking Medicine News(10 mins):